Key Highlights
- Shares are indicated down 7.76% to $0.95 in pre-market trading, against a prior close of $1.03.
- The pullback follows a sharp 39.19% gain in Monday's regular session.
- Monday's rally was driven by news that the FDA lifted a clinical hold on the company's lead drug candidate for TSC-related epilepsy.
- Patient screening for the resulting Phase 2a study is expected to begin by the first quarter of 2027.
- Market Capitalization stands at roughly $49.76 million.
A Pause After a Sharp One-Day Rally
Filana Therapeutics (NASDAQ:FLNA) shares are indicated lower in pre-market trading today, giving back a portion of Monday's sharp 39.19% gain rather than reacting to any new negative development.
The Austin, Texas-based clinical-stage biotechnology company is focused on developing novel therapies to modulate the filamin A protein for central nervous system disorders, with its lead effort centered on treating epilepsy related to Tuberous Sclerosis Complex, a rare genetic disorder that causes seizures in the large majority of patients who have it. Monday's rally followed the company's announcement that the FDA had lifted a clinical hold on its investigational new drug application, clearing the way for a planned Phase 2a study.
What Triggered Monday's Move
The clinical hold lift allows the company to move forward with a 16-week, multicenter, randomized, double-blind trial evaluating two doses of its lead candidate in patients with drug-resistant TSC-related seizures. The study is planned across 13 U.S. sites with a target enrollment of 40 subjects between ages 12 and 55, and patient screening is expected to begin by the first quarter of 2027. Removing a clinical hold is a meaningful regulatory milestone, since it directly determines whether a company can proceed with human trials at all, which explains why Monday's reaction was so large relative to the stock's typical daily moves.
Today's Pullback Reflects Profit-Taking, Not a New Catalyst
A single-day gain of nearly 40% often invites some profit-taking the following session, particularly in a thinly traded, low-priced stock where large percentage swings can happen on relatively modest trading volume. Today's decline does not appear to be tied to any new company-specific news, suggesting it reflects investors locking in gains from Monday's move rather than a reassessment of the trial's prospects.
The Company Says It Is Ready to Move Quickly
Company Leadership has said that trial-readiness work, including engaging a clinical research organization, identifying trial sites, and recruiting investigators, was already completed while the hold was in place, positioning the company to move toward site initiation and patient enrollment without further delay now that the hold has been lifted.






Please wait processing your request...